Contacts: Robert Jaffe/Evan Pondel
PondelWilkinson Inc.
(310) 279-5980

LANNETT COMPANY PROVIDES UPDATE ON MARKETING DIGOXIN TABLETS

Philadelphia, PA – May 15, 2008 – Lannett Company, Inc. (AMEX:LCI), a manufacturer of generic pharmaceuticals, said today that it continues to work closely with the U.S. Food and Drug Administration (FDA) to ensure that an uninterrupted and safe supply of Digoxin Tablets is available for U.S. patients, following the FDA's announced recall of Digitek® brand of Digoxin.

The company said it has secured additional active pharmaceutical ingredient (API) for their Digoxin Tablets and now stands ready to meet U.S. demand for Digoxin Tablets, 0.125 mg and 0.25 mg. According to Wolters Kluwer, total sales of Digoxin Tablets were $126 million in 2007 at average wholesale price (AWP).

"We want to reassure all of our customers as well as the general public that we are prepared to supply this difficult to source medication," said Kevin Smith, Lannett's vice president of sales and marketing.

Digoxin is indicated for the treatment of mild to moderate heart failure as well as for the control of ventricular response rate in patients with chronic atrial fibrillation.

Lannettt Company:

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of indications. For more information, visit Lannett Company's website at www.lannett.com.

# # #